A Phase II Study of IMMU 130 (hMN-14-SN38 Antibody Drug Conjugate) in Patients With Metastatic Colorectal Cancer

Trial Profile

A Phase II Study of IMMU 130 (hMN-14-SN38 Antibody Drug Conjugate) in Patients With Metastatic Colorectal Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Labetuzumab govitecan (Primary)
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Adverse reactions
  • Sponsors Immunomedics
  • Most Recent Events

    • 18 Jan 2017 Results published in an Immunomedics media release.
    • 18 Jan 2017 Status changed from not yet recruiting to active, no longer recruiting, as reported by an Immunomedics media release.
    • 22 Aug 2013 This trial is expected to start in the first quarter of 2014, according to an Immunomedics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top